Targeting Brain Lipid Imbalance in APOE4 Alzheimer's with ACC Molecules
Official title: Targeting Brain Lipid Dysregulation in APOE4 Alzheimer's Disease with ACC Antisense Oligonucleotides
Funded at Mcm6 Therapeutics, INC. · NIH-11406621 · Data updated 2026-11-12
A new approach aims to correct fat and lipid problems in the brains of people at risk for Alzheimer's by using ACC-targeting therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mcm6 Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | September 25, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,284,978 |
| NIH project number | 2R42AG087802-02 |
| Project ID | NIH-11406621 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with APOE4 genotype who have or are at risk for AD dementia.
✕Less likely to help
Individuals without the APOE4 risk allele or without brain lipid dysregulation may not benefit from this specific approach.
What this research studies
This project focuses on people with or at risk for Alzheimer’s disease who carry the APOE4 gene. It builds on prior work in human stem cell models to identify enzymes (ACC1/2) that control brain lipid buildup and tests inhibitors that may reduce harmful lipids in APOE4 brains. The study is designed to move from cell models toward therapies that could be tested in people, with careful evaluation of safety and brain health effects. If successful, this work could slow neurodegeneration by restoring normal lipid balance in brain cells.
Why it matters
Potential benefit: If successful, the research could lead to a therapy that reduces brain lipid abnormalities and slows progression of Alzheimer's disease in APOE4 carriers.
How similar studies have gone: Similar strategies targeting lipid pathways have shown promise in cellular models, but translating to human benefit remains to be proven.
Where this research is happening
-
Mcm6 Therapeutics, INC.
Lexington, United States Active
Researchers
- Principal investigator: Lam, Kelvin T — Mcm6 Therapeutics, INC.
- Study coordinator: Lam, Kelvin T
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.